NCT02437760

The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring

Determination of the Prognostic and Predictive Value of the Cancer Antigen-125 (CA-125) Marker in Lung Cancer Monitoring

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: E-DA Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura. The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
OTHER	serum and pleural effusion CA-125 level	serum and pleural effusion(if exist) CA-125 are collected: * at time of diagnosis * every 3 month during treatment * stop at the progression or after 12 months

Timeline

• Start date: 2015-02-01
• Primary completion: 2017-02-01
• Completion: 2018-02-01
• First posted: 2015-05-08
• Last updated: 2015-05-08

Locations

1 site across 1 country: Taiwan